What's Happening?
CREATE Medicines has dosed the first patient in a Phase 1/2 clinical trial of MT-304, an investigational in vivo CAR therapy targeting HER2-positive solid tumors. This therapy uses CREATE's mRNA-LNP platform to program immune cells within the body, aiming
to engage multiple arms of the immune system for a coordinated attack on cancer cells. The trial will assess the safety, tolerability, and preliminary efficacy of MT-304 in patients with HER2-positive breast and gastric cancers.
Why It's Important?
MT-304 represents a novel approach to cancer treatment, potentially offering a new therapeutic option for patients with HER2-positive cancers who have exhausted existing therapies. By engaging both NK and myeloid cells, this therapy could overcome resistance patterns seen with current treatments, providing more durable responses. The trial's success could pave the way for further advancements in in vivo CAR therapies, expanding treatment possibilities for various cancers.
What's Next?
The ongoing trial will provide critical data on MT-304's efficacy and safety, informing future clinical development and potential regulatory submissions. If successful, CREATE Medicines may expand its platform to target other cancer types and explore additional applications in autoimmunity. The company is also working on advancing other programs in its pipeline, with plans to introduce new therapies into clinical trials within the next year.
